Management of bone metastases in renal cell carcinoma: bone-targeted treatments, systemic therapies, and radiotherapy

Abstract

Metastatic renal cell carcinoma (mRCC) presents with bone metastases in around 20%-30% of patients enrolled in the most recent first-line clinical trials. Emergence of several new agents in first line, in both monotherapy and combination, has significantly improved patient outcomes. However, the activity of such agents on bone metastases is unclear and management of these patients is complex, due to potential complications that can significantly impair quality of life. This review addresses mRCC diagnosis and monitoring and summarizes the current evidence on systemic therapy, ablative therapies such as stereotactic ablative radiotherapy and surgery, and supportive therapy with bone-targeting agents for these patients, with the goal of improving their outcomes.

Keywords

Bone metastases / renal cell carcinoma / bone targeted treatments / radiotherapy / systemic therapy

References

[1] Kim WY.Role of VHL gene mutation in human cancer.J Clin Oncol2004;22:4991-5004

[2] Gong J,Dizman N,Pal SK.Metastasis in renal cell carcinoma: biology and implications for therapy.Asian J Urol2016;3:286-92 PMCID:PMC5730828

[3] Grange C,Collino F.Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche.Cancer Res2011;71:5346-56

[4] Razorenova OV,Colavitti R.VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKC{delta}-driven migration.Proc Natl Acad Sci U S A2011;108:1931-6 PMCID:PMC3033256

[5] Aubert S,Hémon B.MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression.Cancer Res2009;69:5707-15

[6] Struckmann K,Steu S.pVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma.J Pathol2008;214:464-71

[7] Paget S.The distribution of secondary growths in cancer of the breast. 1889.Cancer Metastasis Rev1989;8:98-101

[8] Bianchi M,Jeldres C.Distribution of metastatic sites in renal cell carcinoma: a population-based analysis.Ann Oncol2012;23:973-80

[9] Choueiri TK,Burotto M.CheckMate 9ER InvestigatorsNivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma.N Engl J Med2021;384:829-41

[10] Motzer RJ,Haanen J.Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.N Engl J Med2019;380:1103-15 PMCID:PMC6716603

[11] Rini BI,Stus V.KEYNOTE-426 InvestigatorsPembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.N Engl J Med2019;380:1116-27

[12] Motzer RJ,McDermott DF.CheckMate 214 InvestigatorsNivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma.N Engl J Med2018;378:1277-90 PMCID:PMC5972549

[13] Motzer RJ,Rha SY.Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma.N Engl J Med2021;384:1289-300

[14] Kinnane N.Burden of bone disease.Eur J Oncol Nurs2007;11 Suppl 2:S28-31

[15] Beuselinck B,Rixe O.Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib.Ann Oncol2011;22:794-800

[16] Santoni M,Procopio G.Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?.J Exp Clin Cancer Res2015;34:10 PMCID:PMC4328067

[17] Yuasa T,Yamamoto S.Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis.Clin Exp Metastasis2011;28:405-11

[18] Chen SC.Bone metastases from renal cell carcinoma.Int J Mol Sci2016;17:987

[19] Kume H,Yamada Y.Prognostic factors for renal cell carcinoma with bone metastasis: who are the long-term survivors?.J Urol2011;185:1611-4

[20] Grünwald V,Bex A.An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma.Nat Rev Urol2018;15:511-21 PMCID:PMC7136176

[21] Kang M,Kim J.Prognostic impact of bone metastasis on survival outcomes in patients with metastatic renal cell carcinoma treated by first line tyrosine kinase inhibitors: a propensity-score matching analysis.J Cancer2020;11:7202-8 PMCID:PMC7646162

[22] Steeg PS.Tumor metastasis: mechanistic insights and clinical challenges.Nat Med2006;12:895-904

[23] Wang J,Wang J.The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer.J Biol Chem2008;283:4283-94

[24] Weilbaecher KN,McCauley LK.Cancer to bone: a fatal attraction.Nat Rev Cancer2011;11:411-25 PMCID:PMC3666847

[25] Trouvin AP.Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss.Clin Interv Aging2010;5:345-54 PMCID:PMC3010170

[26] Dougall WC,Charrier K.RANK is essential for osteoclast and lymph node development.Genes Dev1999;13:2412-24 PMCID:PMC317030

[27] Casimiro S,Mansinho A,Costa L.Molecular mechanisms of bone metastasis: which targets came from the bench to the bedside?.Int J Mol Sci2016;17:1415 PMCID:PMC5037694

[28] Paiva R, Gomes I, Casimiro S, Fernandes I, Costa L. c-Met expression in renal cell carcinoma with bone metastases.J Bone Oncol2020;25:100315 PMCID:PMC7527574

[29] Hass R,Yang Y.c-Met expression and activity in urogenital cancers - novel aspects of signal transduction and medical implications.Cell Commun Signal2017;15:10 PMCID:PMC5316205

[30] Birchmeier C,Gherardi E.Met, metastasis, motility and more.Nat Rev Mol Cell Biol2003;4:915-25

[31] Gibney GT,Camp RL.c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.Ann Oncol2013;24:343-9 PMCID:PMC3551486

[32] Mukai S,Kawagoe Y.Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis.Hum Cell2015;28:44-50 PMCID:PMC4286132

[33] Aisen AM,Braunstein EM,Phillips WA.MRI and CT evaluation of primary bone and soft-tissue tumors.AJR Am J Roentgenol1986;146:749-56

[34] O'Sullivan GJ,Cronin CG.Imaging of bone metastasis: an update.World J Radiol2015;7:202-11 PMCID:PMC4553252

[35] Hamaoka T,Podoloff DA,Ueno NT.Bone imaging in metastatic breast cancer.J Clin Oncol2004;22:2942-53

[36] Rieden K.Conventional imaging and computerized tomography in diagnosis of skeletal metastases.Radiologe1995;35:15-20

[37] Pathak AP.Magnetic resonance imaging of tumor physiology.Methods Mol Med2006;124:279-97

[38] Yang HL,Wang XM,Deng SM.Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy.Eur Radiol2011;21:2604-17

[39] Fogelman I,Israel O.Positron emission tomography and bone metastases.Semin Nucl Med2005;35:135-42

[40] Wu HC,Shen YY,Lin CC.Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas - a preliminary report.J Cancer Res Clin Oncol2002;128:503-6

[41] Sohaib SA,Allen SD,Eisen T.Comparison of whole-body MRI and bone scintigraphy in the detection of bone metastases in renal cancer.Br J Radiol2009;82:632-9

[42] Coleman RE.Clinical features of metastatic bone disease and risk of skeletal morbidity.Clin Cancer Res2006;12:6243s-9s

[43] Roelofs AJ,Gordon S.Molecular mechanisms of action of bisphosphonates: current status.Clin Cancer Res2006;12:6222s-30s

[44] Elomaa I,Porkka L.Treatment of skeletal disease in breast cancer: a controlled clodronate trial.Bone1987;8 Suppl 1:S53-6

[45] Paterson AH,Kanis JA,Hanson J.Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.J Clin Oncol1993;11:59-65

[46] Hortobagyi GN,Porter L.Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.N Engl J Med1996;335:1785-91

[47] Theriault RL,Hortobagyi GN.Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group.J Clin Oncol1999;17:846-54

[48] Rosen LS,Kaminski M.Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.Cancer J2001;7:377-87

[49] Costa L.Which bisphosphonate to treat bone metastases?.Lancet Oncol2014;15:15-6

[50] Rosen LS,Tchekmedyian S.Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.J Clin Oncol2003;21:3150-7

[51] Broom RJ,Sharples K.Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.Clin Genitourin Cancer2015;13:50-8

[52] Lipton A,Stopeck AT.Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.Eur J Cancer2012;48:3082-309

[53] Lacey DL,Simonet WS.Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.Nat Rev Drug Discov2012;11:401-19

[54] Henry DH,Goldwasser F.Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.J Clin Oncol2011;29:1125-32

[55] Motzer RJ,Cella D.Pazopanib versus sunitinib in metastatic renal-cell carcinoma.N Engl J Med2013;369:722-31

[56] Costa L,Saad F.Denosumab and zoledronic acid treatment in patients with genitourinary cancers and bone metastases.JCO2013;31:5079-5079

[57] Stopeck AT,Body JJ.Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.Support Care Cancer2016;24:447-55 PMCID:PMC4669370

[58] Guillot A,Barthélémy P.Denosumab toxicity when combined with anti-angiogenic therapies on patients with metastatic renal cell carcinoma: a GETUG study.Clin Genitourin Cancer2019;17:e38-43

[59] Fusco V,Saia G.Osteonecrosis of the jaw in patients with metastatic renal cell cancer treated with bisphosphonates and targeted agents: results of an italian multicenter study and review of the literature.Clin Genitourin Cancer2015;13:287-94

[60] McKay RR,Gray KP.Radium-223 dichloride in combination with vascular endothelial growth factor-targeting therapy in advanced renal cell carcinoma with bone metastases.Clin Cancer Res2018;24:4081-8 PMCID:PMC6688176

[61] Beisland C,Klepp O.Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study.Onco Targets Ther2017;10:371-85 PMCID:PMC5248939

[62] Chang AJ,Zhu Z.The past, present and future of immunotherapy for metastatic renal cell carcinoma.Anticancer Res2019;39:2683-7

[63] Schultze-Seemann W,Tschechne B.Bevacizumab plus IFN-alpha-2a in first-line treatment of patients with advanced or metastatic renal cell carcinoma: a prospective German non-interventional study.Anticancer Res2019;39:875-82

[64] Maita .et al. Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function.Int J Cancer2012;130:677-84

[65] Kalra S,Atkinson BJ.Outcomes of patients with metastatic renal cell carcinoma and bone metastases in the targeted therapy era.Clin Genitourin Cancer2017;15:363-70

[66] Zołnierek J,Langiewicz P.Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases.J Cancer Res Clin Oncol2010;136:371-78

[67] Choueiri TK,Powles T.METEOR InvestigatorsCabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.N Engl J Med2015;373:1814-23 PMCID:PMC5024539

[68] Escudier B,Motzer RJ.Cabozantinib, a New Standard of care for patients with advanced renal cell carcinoma and bone metastases?.J Clin Oncol2018;36:765-72 PMCID:PMC6804840

[69] Motzer RJ,McDermott DF.CheckMate 025 InvestigatorsNivolumab versus everolimus in advanced renal-cell carcinoma.N Engl J Med2015;373:1803-13 PMCID:PMC5719487

[70] Fioramonti M,Iuliani M.Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions.Oncotarget2017;8:20113-21 PMCID:PMC5386748

[71] Escudier B,McDermott DF.CheckMate 025 investigatorsCheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma.Eur Urol2017;72:962-71

[72] Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Denosumab and pembrolizumab in clear cell renal carcinoma: a Phase II Trial (ANZUP 1601). Available from: https://clinicaltrials.gov/ct2/show/NCT03280667 [Last accessed on 6 Jul 2021]

[73] Motzer RJ,Michaelson MD.NCCN guidelines insights: kidney cancer, version 2.2020.J Natl Compr Canc Netw2019;17:1278-85

[74] Zelefsky MJ,Motzer R.Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma.Int J Radiat Oncol Biol Phys2012;82:1744-8 PMCID:PMC4034682

[75] Jhaveri PM,Paulino AC.A dose-response relationship for time to bone pain resolution after stereotactic body radiotherapy (SBRT) for renal cell carcinoma (RCC) bony metastases.Acta Oncol2012;51:584-8

[76] Wang XS,Shiu AS.Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial.Lancet Oncol2012;13:395-402 PMCID:PMC3605896

[77] Dabestani S,Hofmann F.Local treatments for metastases of renal cell carcinoma: a systematic review.Lancet Oncol2014;15:e549-61

[78] Du Y,Hadaschik B.Survival and prognostic factors of patients with renal cell cancer with bone metastasis in the era of targeted therapy: a single-institution analysis.Urol Oncol2016;34:433.e1-8

[79] Kato S,Demura S.Spinal metastasectomy of renal cell carcinoma: a 16-year single center experience with a minimum 3-year follow-up.J Surg Oncol2016;113:587-92

[80] Hunter GK,Koyfman SA.The efficacy of external beam radiotherapy and stereotactic body radiotherapy for painful spinal metastases from renal cell carcinoma.Pract Radiat Oncol2012;2:e95-e100

[81] Teyssonneau D,Domblides C.Treatment of spinal metastases in renal cell carcinoma: a critical review.Crit Rev Oncol Hematol2018;125:19-29